Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Niclosamide - Hyundai Bioscience

Next Previous
Drug Profile

Niclosamide - Hyundai Bioscience

Alternative Names: CP-COV03; CP-PCA07; Niclosamide dehydrotalcite-Hyundai Bioscience; Poly-COV01; Xafty

Latest Information Update: 10 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hyundai Bioscience
  • Developer CNPharm; Hyundai Bioscience
  • Class Anthelmintics; Anti-inflammatories; Antibacterials; Antineoplastics; Antivirals; Benzamides; Chlorophenols; Nitrobenzenes; Skin disorder therapies; Small molecules
  • Mechanism of Action Autophagy stimulants; Mitochondrial oxidative phosphorylation uncouplers; MTOR protein inhibitors; NF-kappa B inhibitors; Notch signalling pathway inhibitors; STAT3 transcription factor inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III COVID 2019 infections; Dengue
  • Preclinical Ebola virus infections; Hantavirus infections; Rheumatoid arthritis
  • No development reported Monkeypox

Most Recent Events

  • 06 Jul 2026 Hyundai Bioscience plans a phase I trial for Prostate cancer (Hormone refractory, Second-line therapy or greater, Combination therapy) in South Korea (PO) in July 2026 (NCT07683013)
  • 28 Jun 2026 No recent reports of development identified for preclinical development in Monkeypox in South Korea (PO)
  • 20 May 2026 Adverse events data from a phase-II/III trial in Dengue released by Hyundai Bioscience

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top